至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands

Chem Sci. 2021-04; 
Elaine C Petronilho, Murilo M Pedrote, Mayra A Marques, Yulli M Passos, Michelle F Mota, Benjamin Jakobus, Gileno Dos Santos de Sousa, Filipe Pereira da Costa, Adriani L Felix, Giulia D S Ferretti, Fernando P Almeida, Yraima Cordeiro, Tuane C R G Vieira, Guilherme A P de Oliveira, Jerson L Silva
Products/Services Used Details Operation
Catalog Antibody R249S – 5′-gcatgaaccggagccccatcctcacca-3′ and 5′-tggtgaggatggggctccggttcatgc-3′. P53C-EGFP wt, M237I, and R249S were inserted into pET24a by Genscript Get A Quote

摘要

Mutant p53 tends to form aggregates with amyloid properties, especially amyloid oligomers inside the nucleus, which are believed to cause oncogenic gain-of-function (GoF). The mechanism of the formation of the aggregates in the nucleus remains uncertain. The present study demonstrated that the DNA-binding domain of p53 (p53C) underwent phase separation (PS) on the pathway to aggregation under various conditions. p53C phase separated in the presence of the crowding agent polyethylene glycol (PEG). Similarly, mutant p53C (M237I and R249S) underwent PS; however, the process evolved to a solid-like phase transition faster than that in the case of wild-type p53C. The data obtained by microscopy of live cells indicat... More

关键词